Advanced in X-Linked Spondyloepiphyseal Dysplasia Tarda

Reiko Horikawa

Tokyo, JP 
Advanced in X-Linked Spondyloepiphyseal Dysplasia Tarda
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Reiko Horikawa practices in Tokyo, Japan. Ms. Horikawa is rated as an Advanced expert by MediFind in the treatment of X-Linked Spondyloepiphyseal Dysplasia Tarda. Her top areas of expertise are Rommen Mueller Sybert Syndrome, Noonan Syndrome, Short Stature (Growth Disorders), Liver Transplant, and Hormone Replacement Therapy (HRT).

Her clinical research consists of co-authoring 167 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles in the study of X-Linked Spondyloepiphyseal Dysplasia Tarda.

Gender
Female

Locations

Tokyo, Japan
Other Locations
Setagaya, 1578535, Japan
Japan
Okura, 1578535, Japan
Hongo, 1130033, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

167 Total Publications

Trends In Reported Outcomes For Growth Hormone Therapy In Children With Growth Hormone Deficiency.
Trends In Reported Outcomes For Growth Hormone Therapy In Children With Growth Hormone Deficiency.
Journal: The Journal of clinical endocrinology and metabolism
Published: July 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Horikawa's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 20 Advanced Conditions
View All 46 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile